AR051723A1 - Utilizacion de agonistas del ppar para el tratamiento de la insuficiencia cardiaca congestiva - Google Patents

Utilizacion de agonistas del ppar para el tratamiento de la insuficiencia cardiaca congestiva

Info

Publication number
AR051723A1
AR051723A1 ARP050105284A ARP050105284A AR051723A1 AR 051723 A1 AR051723 A1 AR 051723A1 AR P050105284 A ARP050105284 A AR P050105284A AR P050105284 A ARP050105284 A AR P050105284A AR 051723 A1 AR051723 A1 AR 051723A1
Authority
AR
Argentina
Prior art keywords
treatment
ppar agonists
cardiac insufficiency
congestive cardiac
congestive
Prior art date
Application number
ARP050105284A
Other languages
English (en)
Spanish (es)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR051723A1 publication Critical patent/AR051723A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ARP050105284A 2004-12-17 2005-12-15 Utilizacion de agonistas del ppar para el tratamiento de la insuficiencia cardiaca congestiva AR051723A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04029946A EP1671633A1 (en) 2004-12-17 2004-12-17 Use of PPAR agonists for the treatment of congestive heart failure

Publications (1)

Publication Number Publication Date
AR051723A1 true AR051723A1 (es) 2007-01-31

Family

ID=34927823

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105284A AR051723A1 (es) 2004-12-17 2005-12-15 Utilizacion de agonistas del ppar para el tratamiento de la insuficiencia cardiaca congestiva

Country Status (16)

Country Link
US (1) US7601863B2 (cg-RX-API-DMAC7.html)
EP (2) EP1671633A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008524129A (cg-RX-API-DMAC7.html)
KR (1) KR20070086332A (cg-RX-API-DMAC7.html)
CN (1) CN101072557A (cg-RX-API-DMAC7.html)
AR (1) AR051723A1 (cg-RX-API-DMAC7.html)
AT (1) ATE498400T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005315920A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0519661A2 (cg-RX-API-DMAC7.html)
CA (1) CA2590391A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005026443D1 (cg-RX-API-DMAC7.html)
IL (1) IL183810A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007006678A (cg-RX-API-DMAC7.html)
MY (1) MY141010A (cg-RX-API-DMAC7.html)
TW (1) TW200635584A (cg-RX-API-DMAC7.html)
WO (1) WO2006063715A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399777B2 (en) 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
HUE055678T2 (hu) 2016-10-05 2021-12-28 Mitobridge Inc PPAR agonista vegyületek kristályos és só alakjai

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE368037T1 (de) * 1999-04-28 2007-08-15 Sanofi Aventis Deutschland Di-aryl-säurederivate als ppar rezeptor liganden
RU2330846C2 (ru) * 2001-08-31 2008-08-10 Санофи-Авентис Дойчланд Гмбх Диарилциклоалкильные производные, способ их получения и их применение в качестве ppar-активаторов
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
US6989462B2 (en) * 2003-03-25 2006-01-24 Sanofi-Aventis Deutschland Gmbh Synthesis of 2-chloromethyl-6-methylbenzoic ester
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators

Also Published As

Publication number Publication date
US7601863B2 (en) 2009-10-13
MX2007006678A (es) 2007-08-14
CN101072557A (zh) 2007-11-14
TW200635584A (en) 2006-10-16
BRPI0519661A2 (pt) 2009-03-03
CA2590391A1 (en) 2006-06-22
WO2006063715A1 (en) 2006-06-22
MY141010A (en) 2010-02-25
JP2008524129A (ja) 2008-07-10
ATE498400T1 (de) 2011-03-15
DE602005026443D1 (de) 2011-03-31
IL183810A0 (en) 2007-10-31
AU2005315920A1 (en) 2006-06-22
KR20070086332A (ko) 2007-08-27
EP1671633A1 (en) 2006-06-21
US20080039512A1 (en) 2008-02-14
EP1827425B1 (en) 2011-02-16
EP1827425A1 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
MX2015017865A (es) Compuestos de pirimidinodiona contra estados cardiacos.
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
CY1117317T1 (el) Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
CR9378A (es) Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias
CY1113924T1 (el) Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
CL2009001044A1 (es) Compuestos cristalinos derivados de heterociclos puenteados por un alqueno; utiles en el tratamiento de enfermedades metabolicas, enfermedades circulatorias, enfermedades del snc, entre otras enfermedades.
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
EA200701845A1 (ru) Рофлумиласт для лечения сахарного диабета
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
MX2020011100A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
CY1112614T1 (el) Αγωγη με κλαδριβινη για τη θεραπεια πολλαπλης σκληρυνσης
CY1114880T1 (el) Αγωνιστες mglu2
ATE499344T1 (de) Peri-substituierte bicyclische sulfonamide gegen arterielle verschlusskrankheit
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
EA202091533A1 (ru) Способы лечения диабета, гепатита и/или воспалительного заболевания печени
EA201000069A1 (ru) Новые гербициды
EA200701592A1 (ru) Композиты и способы их получения и использования
CL2007001747A1 (es) Compuestos derivados de aril y heteroaril-etil-acilguanidina; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y prevencion de la hipertension, insuficiencia cardiaca y afecciones renales entre otras.
AR051723A1 (es) Utilizacion de agonistas del ppar para el tratamiento de la insuficiencia cardiaca congestiva
BR112022017283A2 (pt) Cristalização de 2?-fl
GT200800296A (es) Derivados de ácido fenilacético
BRPI0511125A (pt) usos de ácido 5,6,7-triidroxieptanóico seus e análogos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal